Market Share Breakdown of Allergy Immunotherapy Providers

Allergy Immunotherapy Market Share Analysis Outlook From 2025 to 2035

The global allergy immunotherapy market consists of multinational pharmaceutical companies, regional healthcare providers, biotechnology firms, and specialty immunotherapy developers.

The market is primarily dominated by leading pharmaceutical companies such as ALK Abello, Stallergenes Greer and Allergy Therapeutics, which collectively hold approximately 34.1% of the market. These companies focus on advanced immunotherapy formulations, precision-targeted allergens, and innovative drug delivery mechanisms.

Regional companies like Anergis, DBV Technologies, Dermapharm Holdings, and others contribute to a regional market share of about 42.3%, offering cost-effective solutions along with some niche allergy treatments.

With new and established pure pharmaceutical companies or biotechnology businesses involved, allergy immunotherapy exhibits a highly competitive market that accelerates innovation, consequently driving this market.

Market participants are working to enhance standards for allergenic extracts, focus on technological enhancement, and adopt novel formulations that help in further therapies, like subcutaneous immunotherapy or SLIT. The rigid regulatory compliances laid by the FDA, EMA, and the Paul Ehrlich Institute invite a great degree of investments into clinical trials for product safety and efficacy standardizations.

Therefore, the competitive strategies involved in this market broadly include product differentiation, innovation related to research, and geographical expansion. Thus, Tier 1 companies hold an uptight lead in the global market owing to their well-established portfolios of FDA and EMA-approved SLIT tablets and SCIT formulations.

Tier 2 and regional players are now eyeing cost-effective solutions for the emerging markets, where affordability and accessibility are reckoned as the prime growth drivers.

Detailed Market Share Analysis

Global Market Share & Industry Share (%)

Global Market Share 2025	Industry Share (%)
Top 3 (ALK Abello, Stallergenes Greer and Allergy Therapeutics)	34.1%
Rest of Top 5 (ALK Abello, Stallergenes Greer and Allergy Therapeutics, HAL Allergy Group and Biomay AG)	56.3%
Emerging & Regional Players	14.5%

Market Concentration Assessment

The market is highly concentrated with Top Players collectively holds around 60.8%.

Segment Analysis

Product Categories

The allergy immunotherapy market can be segmented based on sublingual immunotherapy tablets, including Odactra, Grastek, Ragwitek, Oralair, and Actair, apart from oral and injections.

Since these are easily administered, non-invasive in nature, and have a good patient compliance record, SLIT tablets are thus an emerging segment. These sublingual formulations are effective and long-lasting to treat respiratory allergies and are securing regulatory approvals all over the world.

Injectable immunotherapy comprises subcutaneous allergy shots that dominate the market share at 66.3%. While requiring frequent administration, these injections remain a highly effective treatment for severe allergies, offering long-term desensitization and symptom reduction.

Continuous advancements in formulation and delivery methods are improving patient compliance and treatment outcomes, further solidifying injectable immunotherapy as a key segment in allergy management.

Immunotherapy Types

The market is further classified based on immunotherapy type:

• Sublingual Immunotherapy (SLIT): SLIT is mainly known for its ease and comfort due to the fact that patients are able to perform the treatment by themselves at home and without the hassle of constant clinic visits. Convenience, therefore, greatly improves compliance and long-term adherence by patients to lighten the burden brought on by injections. Additionally, SLIT has shown an extremely favorable safety profile; fewer adverse reactions are seen as compared to conventional subcutaneous immunotherapy. Its non-invasive nature makes it particularly appealing for pediatric and needle-averse patients, increasing accessibility to allergy immunotherapy.
• Subcutaneous Immunotherapy (SCIT): SCIT has been clinically proven to give sustained relief, thus being the best option for patients with severe or persistent allergies. Though its course requires frequent visits to clinics for injections, its long-term benefits outweigh the inconvenience. The ongoing development of new formulations and methods of administration improves efficacy, safety, and patient compliance of SCIT.
• Specific Immunotherapy (SIT): Specific immunotherapy applies specific desensitization methods to the individual allergens of the patient, training the immune system to gradually tolerate specific triggers.

Indications

Allergy immunotherapy treatments cater to multiple allergic conditions:

• Allergic Asthma: The main solution of immunotherapy is the decrease in the characteristic respiratory inflammation and hypersensitivity that occur with allergic asthma. In fact, the treatments are proved to lessen the airway reactivity gradually, desensitize the immune system from allergens, evade critical asthma attacks, and show improved lung functions over time.

Year on Year Leaders

2024 has been a year of transformation in the allergy immunotherapy market, wherein leading companies furthered precision immunotherapy and newer modes of treatment:

• ALK-Abelló (SLIT-based Therapies): With its development in SLIT-based allergy therapies, ALK-Abelló has extended the portfolio of patient-friendly tablets to a variety of allergens. The company worked on increasing compliance with treatments due to innovative development of drug formulations and education programs for patients. With approvals in all major regulatory markets, ALK-Abelló expedited SLIT as the mainstream solution for allergy immunotherapy. Furthermore, it is investing in research to develop the efficacy of its SLIT products for newer allergens, with better results in desensitization. With strategic partners and market coverage, ALK-Abelló is set to continue pushing the boundaries within allergy immunotherapy, ensuring accessibility and improving treatment experiences across different parts of the world.
• Stallergenes Greer (Personalized Allergy Treatments): With its precision immunotherapy solutions, Stallergenes Greer pioneers allergen formulations to match patient-specific sensitization and enhances research in personalized desensitization techniques. The company is enhancing efficacy and safety with advanced diagnostics and molecular profiling. Furthermore, the company is extending clinical trials to validate long-term benefits that will ensure wider adoption of tailored allergy therapies.

Key Highlights from the Forecast

Rise of SLIT Therapies

The growing patient preference for sublingual immunotherapy (SLIT) tablets is driven by their ease of administration, reduced side effects, and ability to be taken at home.

These tablets eliminate the need for frequent clinic visits, making them a convenient alternative to allergy shots. SLIT is particularly appealing to pediatric and needle-averse patients, as it offers a non-invasive way to build tolerance to allergens over time. Additionally, SLIT has demonstrated a strong safety profile, with fewer severe reactions compared to subcutaneous immunotherapy.

Expansion of Oral Immunotherapy for Food Allergies

Oral immunotherapies for life-threatening food allergies see a rapid rise in use due to their potential induction of long-term tolerance against such allergens.

These function by exposing patients in a controlled manner to doses of allergens, which are strengthening immune resistance and thereby reducing adverse reactions. Clinical trials have realized tremendous success in desensitizing patients, reducing the risk of anaphylaxis, and improving safety profiles.

As more regulatory approvals are gained and access to innovative oral treatments like Palforzia increases, more sufferers from food allergy can be treated effectively with long-term training of the immune system. With their growing use, these therapies are transforming food allergy management and improving the quality of life in patients.

Tier-Wise Company Classification 2025

By Tier Type	Example of Key Players
Tier 1	ALK Abello, Stallergenes Greer, Allergy Therapeutics
Tier 2	HAL Allergy Group, Biomay AG, HollisterStier Allery and Desentum OY
Tier 3	Emerging biotech firms and specialty providers

Key Company Initiatives

Brand	Key Focus
ALK-Abelló	Expanding SLIT therapy portfolio and enhancing regulatory approvals.
Stallergenes Greer	Advancing personalized allergy immunotherapy solutions.
LETI Pharma	Improving biologic standardization of allergen extracts.
Allergy Therapeutics	Developing next-generation injectable immunotherapy.
HollisterStier	Investing in biologic allergy treatment innovations.

Advice for Industry Players

• Investment in Biologic Immunotherapy: Further research in biologic immunotherapy using monoclonal antibodies would better target highly specific immune pathways responsible for the allergic reaction, reduce adverse effects, and enhance long-term tolerance to offer effective and personalized immunotherapeutic solutions for patients. Currently, ongoing clinical trials and some approvals by the regulatory authorities push forward the frontiers of using such advanced biologic treatments in allergy care.
• Digitalization and Telehealth Integration: Improvement of e-commerce sales and virtual consultations for easy access by allowing the fulfillment of the prescription remotely, assessment of allergy digitally, and real-time consultation. These developments improve patient engagement, timely treatment, and wider market access for the solutions of allergy immunotherapy.
• Multi-Allergen Immunotherapy Development: Innovating combination immunotherapy solutions that simultaneously target multiple allergens is enhancing treatment efficiency, reducing overall therapy duration, and improving patient compliance. These advancements provide broader desensitization, ensuring long-term relief and personalized allergy treatment options.
• Expansion into Emerging Markets: Expanding into high-growth regions by forming strategic partnerships, securing regulatory approvals, and improving access to allergy immunotherapy solutions. Strengthening local collaborations enhances market penetration, ensuring wider availability of advanced allergy treatments to underserved populations.

Future Roadmap

• AI-Powered Allergy Diagnosis: Artificial intelligence-driven diagnostic tools are transforming allergy care by enhancing identification accuracy and enabling personalized treatment plans. AI-powered systems analyze vast patient data, detect patterns in allergic responses, and predict treatment efficacy. These innovations streamline diagnostics, reduce misdiagnosis rates, and support physicians in tailoring immunotherapy solutions for improved patient outcomes and long-term relief.
• Sustainable Allergen Manufacturing: Ongoing research into eco-friendly production of allergen extracts is optimizing supply chain sustainability by reducing environmental impact, enhancing extraction efficiency, and minimizing waste. Innovations in green chemistry and biodegradable materials are making allergen production more sustainable, ensuring long-term industry growth while maintaining high safety and efficacy standards in immunotherapy solutions.
• Oral Immunotherapy Advancements: Expanding oral-based treatments for complex allergies, improving patient adherence and long-term desensitization success.

Table of Content

1. Competition Analysis Outlook
2. Detailed Market Share Analysis
3. Segmental Analysis
4. Year over Year Leaders
5. Highlights from the Forecast
6. Tier Wise Industry Classification
7. Key Company Initiatives
8. Recommendation for Suppliers
9. Future Roadmap